Paper - Review

DOI: 10.1016/j.cell.2020.09.053

Abstract

The results of a phase 1B study
← in which a personalized neo-antigen vaccine
→ was combined ← with programmed death receptor-1 blockade
← in patients ← with advanced cancers

The study
→ provides → a framework → for combinatorial vaccine therapies
→ that could 1⃣ mount robust T-cell response 2⃣ enhance tumor killing 3⃣ provide clinical benefit

---